充血性心力衰竭 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus
Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction
Modifiable lifestyle factors and heart failure: A Mendelian randomization study
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure
Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure
Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure
Dilated cardiomyopathy: so many cardiomyopathies!
Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry
Heart Failure and Atrial Fibrillation, Like Fire and Fury

Original Research

2019 May;21(5):665-675.

JOURNAL：Eur J Heart Fail.

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators.

4500

Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF